

TOGAS – TOWARDS GASTRIC CANCER SCREENING IMPLEMENTATION IN THE EUROPEAN UNION – WP 4 PILOT STUDY

Marcel Kralj

UEG Week Berlin 2025

Poster

Stomach & H. Pylori

October 6, 2025

An ongoing six-country EU screen-and-treat study for *Helicobacter pylori* in asymptomatic 30–34 year olds shows variable response rates and high eradication rates with acceptable safety profiles.

KEY POINTS

- Interim results show wide variation in invitation response rates across sites, ranging from 4.1% in Wroclaw to 45.5% in Ljubljana, and seropositivity or urea breath test positivity rates from 13.9% to 49%.
- Eradication rates ranged from 88.2% to 96.9% across study sites using three different first-line therapy regimens including bismuth-based quadruple therapy and triple therapy, with no serious adverse events reported.
- The study uses a centralized data capture system for quality control and employs locally validated *H. pylori* IgG serologies or urea breath tests with free testing and treatment for eligible participants.
- Differences among sites in organization, educational campaigns, and launch timing highlight the importance of careful planning and public awareness campaigns to increase participation rates in organized screening programs.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/eb3e7cd2-a814-11f0-b072-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.